Epitome Therapeutics is developing a proprietary epigenome editing platform called CADENCE that aims to enable precise, durable and calibrated activation of gene expression without changing DNA sequence. The platform uses a modular architecture built around a library of engineered epigenetic effectors intended to tailor gene activation to specific biological contexts. The company was founded in 2025 as a spin-off from EMBL and is focused on translating its science into development programmes and selecting a first drug candidate. Financially, Epitome closed a €4 million pre-seed financing (€2M equity plus €2M grants) to advance the platform and grow its team. The company plans to use the new capital to advance development programmes and expand its headcount as it progresses toward initial therapeutic milestones.

Total raised

$5M

Funding rounds

2

Latest round

Grant

Latest activity

Jun 2026